Business
Bell Potter thinks the Mesoblast (ASX:MSB) share price can run higher
Well, 2020 was yet another rollercoaster ride for the Mesoblast Limited (ASX: MSB) share price, as good and bad news pushed and pulled on the company’s shares.
The latest piece of disappointing news from Mesoblast was on its remestemcel-L product. This is used for ventilator dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection.
The Mesoblast share price spiralled 45% lower when the trial was reported to be unlikely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment.
Despite the trial shortcomings, Bell Potter maintained a speculative buy recommendation on Mesoblast shares on 23 December 2020. The broker updated its Mesoblast share…
-
Noosa News14 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
Noosa News22 hours agoNT cattle rustler fined almost $430k for stealing 116 head from neighbouring station
-
Business23 hours agoRevenue growth, profit margin pressures, and a $365m buyback
-
Noosa News16 hours agoFuel tanker racing to unload in Darwin ahead of Tropical Cyclone Fina